# Dupilumab in Chinese Adult Participants With CRSwNP

> **NCT05878093** · PHASE3 · COMPLETED · sponsor: **Sanofi** · enrollment: 63 (actual)

## Conditions studied

- Chronic Rhinosinusitis With Nasal Polyps

## Interventions

- **DRUG:** Dupilumab
- **DRUG:** Placebo
- **DRUG:** Budesonide

## Key facts

- **NCT ID:** NCT05878093
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-05-16
- **Primary completion:** 2024-09-06
- **Final completion:** 2024-11-28
- **Target enrollment:** 63 (ACTUAL)
- **Last updated:** 2025-09-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05878093

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05878093, "Dupilumab in Chinese Adult Participants With CRSwNP". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05878093. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*